Spyre Therapeutics, Inc. $SYRE Shares Sold by TD Asset Management Inc

TD Asset Management Inc cut its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 36.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,368 shares of the company’s stock after selling 41,600 shares during the quarter. TD Asset Management Inc’s holdings in Spyre Therapeutics were worth $1,213,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Affinity Asset Advisors LLC boosted its holdings in Spyre Therapeutics by 26.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 606,678 shares of the company’s stock valued at $9,082,000 after acquiring an additional 125,000 shares during the period. AlphaQuest LLC lifted its position in shares of Spyre Therapeutics by 1,485.1% during the third quarter. AlphaQuest LLC now owns 66,163 shares of the company’s stock worth $1,109,000 after purchasing an additional 61,989 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Spyre Therapeutics by 4.6% in the second quarter. Franklin Resources Inc. now owns 795,275 shares of the company’s stock valued at $11,905,000 after purchasing an additional 34,647 shares during the period. Candriam S.C.A. boosted its stake in shares of Spyre Therapeutics by 64.4% in the third quarter. Candriam S.C.A. now owns 404,362 shares of the company’s stock valued at $6,777,000 after purchasing an additional 158,332 shares during the period. Finally, Intech Investment Management LLC grew its holdings in shares of Spyre Therapeutics by 22.1% in the second quarter. Intech Investment Management LLC now owns 24,945 shares of the company’s stock valued at $373,000 after purchasing an additional 4,517 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

NASDAQ:SYRE opened at $40.59 on Friday. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $45.76. The firm has a market capitalization of $3.19 billion, a PE ratio of -19.51 and a beta of 3.09. The business’s fifty day moving average price is $35.04 and its 200 day moving average price is $26.93.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.04). As a group, equities analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Insider Buying and Selling

In other news, CFO Scott L. Burrows sold 2,500 shares of Spyre Therapeutics stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.65, for a total value of $101,625.00. Following the transaction, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at $3,983,456.10. The trade was a 2.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the sale, the chief executive officer owned 657,540 shares of the company’s stock, valued at approximately $21,567,312. This trade represents a 2.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 47,500 shares of company stock worth $1,686,675. Insiders own 15.43% of the company’s stock.

Analyst Upgrades and Downgrades

SYRE has been the topic of a number of research reports. Wells Fargo & Company increased their target price on shares of Spyre Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. BTIG Research reiterated a “buy” rating and issued a $70.00 price objective on shares of Spyre Therapeutics in a research note on Friday, February 20th. Wall Street Zen lowered Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Citigroup began coverage on Spyre Therapeutics in a report on Wednesday, December 17th. They set a “buy” rating and a $64.00 price target on the stock. Finally, Leerink Partners raised Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Spyre Therapeutics presently has an average rating of “Buy” and an average target price of $53.44.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.